about
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumorsTargeted therapy for hepatocellular carcinoma: novel agents on the horizonTargeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cellsA meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell linesReactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells.BCKDK of BCAA Catabolism Cross-talking With the MAPK Pathway Promotes Tumorigenesis of Colorectal CancerEngineered single nucleotide polymorphisms in the mosquito MEK docking site alter Plasmodium berghei development in Anopheles gambiae.Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.Immunological hurdles of ageing: indispensable research of the human model.U0126 protects cells against oxidative stress independent of its function as a MEK inhibitor.Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants.CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapyMetastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months.Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.MEK inhibitors: a patent review 2008 - 2010.Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.Kinase inhibitors for CNS diseases: an analysis of the recent patent literature.The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.Signaling pathways as therapeutic targets in biliary tract cancer.Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling.Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancerRaf/MEK/ERK signaling inhibition enhances the ability of dequalinium to induce apoptosis in the human leukemic cell line K562.Biology using engineering tools: the negative feedback amplifier.MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myelomaPhosphorous dysregulation induced by MEK small molecule inhibitors in the rat involves blockade of FGF-23 signaling in the kidney.Aldosterone activates the oncogenic signals ERK1/2 and STAT3 via redox-regulated mechanisms.Current Development Status of MEK Inhibitors.The role of Raf-1 kinase in diabetic retinopathy.
P2860
Q24294914-7F5AD1CD-A694-42BB-9AA3-15F9256483D5Q27002288-6C62DB69-4460-4395-89EE-54B2F35C5BC0Q28484496-2A99D1D5-02F7-4BEB-969C-5D9853EBE55BQ28540936-CF701048-8C51-4791-BFC5-315A2AC1C92AQ33713850-7E903C2F-5093-4568-A3A2-737FCBF40351Q33817695-3EEB8FC7-E109-4880-BFE0-568B7287EB6EQ33830233-F54CAFF4-15A4-49CD-B1A8-8426690D01D1Q34168357-BDFC5B19-B232-4357-BEF9-6111F3642A88Q34307356-59F9F50F-F5AB-4397-915C-40D6F32AAD59Q34966603-BA59CF31-F124-4245-B908-589ECAEFEA65Q34995544-000DC5F1-1DFD-4AFC-BFF4-9A4FC8B3229DQ35006087-DA594EB9-5695-4DD0-83D7-CA35078F2E7AQ35558993-BBB55055-D206-4150-88DC-0CAA10C6C1B7Q35679353-291B5558-8C49-4332-A1A6-CAA26E636314Q35987390-BB635272-4BDE-4AD1-8962-FD0CCC7FE6E6Q36351612-0E2F800A-A068-491C-8D30-0DACE1B1F39FQ36813976-80506E8E-AD4C-43C6-A3FD-7C4AB3488A47Q36862768-96C785B4-10B1-485E-AC34-C6FD97361F4EQ37192616-69D6FE78-6467-4AAE-BA6A-CCAD3095D0CDQ37715539-F5674DDD-8942-4413-A505-14DB651619F3Q37837732-F1A9406D-3A6D-4C8D-8CC5-B863FF551A4FQ37865381-F4FA967A-8C33-4AF4-90BB-AB942D23C355Q37872791-FB96A015-D4DA-4E37-B2C9-0E4186B9B027Q38053855-29B77D09-63C2-420E-9AEF-E6F870378A3EQ38162917-CFC59556-3A73-4752-A8DB-AC2EE67FA250Q38397326-F21E49EF-1C53-46F8-A54E-770AA7AEA037Q38747573-B2518FFF-4B91-4E6F-829B-495AB72AC742Q38884628-D7E75AC6-56F3-4951-BBCC-FD27C4801A39Q39186250-6EFB1ABF-CC31-4892-AA39-56D058B049C4Q39300516-37216814-2873-4E6C-B596-EAAEF9BDC984Q41848152-FD776DD3-868B-41C5-99C7-0CCE1D8AC241Q42608339-6835CB88-96C5-4647-BEF0-24BFC0E96CDAQ42726284-2BC8D6D9-6886-4942-AB29-DD96B6317AB8Q45015877-315B75E4-B7B5-41F5-8DA9-AE6778C56437Q47735535-242FF8C2-A4B4-49BB-A35C-A65DCDFA76CAQ54618543-EEFA53F3-49F6-4A96-9418-926D4D24C3FE
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging MEK inhibitors.
@en
Emerging MEK inhibitors.
@nl
type
label
Emerging MEK inhibitors.
@en
Emerging MEK inhibitors.
@nl
prefLabel
Emerging MEK inhibitors.
@en
Emerging MEK inhibitors.
@nl
P2093
P2860
P50
P1476
Emerging MEK inhibitors
@en
P2093
Agostino Tafuri
Alberto M Martelli
Antonio Bonati
Ferdinando Nicoletti
Franca Stivala
Linda S Steelman
Melchiorre Cervello
Michele Milella
Steven L Abrams
P2860
P304
P356
10.1517/14728210903282760
P407
P577
2010-06-01T00:00:00Z